Eltanexor: Advancing XPO1 Inhibitor Applications in Cance...

2025-10-18

Eltanexor (KPT-8602) is redefining cancer research with its potent, oral inhibition of XPO1—unlocking new strategies in both hematological and solid tumor studies. This article translates cutting-edge bench findings into actionable protocols, highlights comparative advantages over earlier nuclear export inhibitors, and delivers troubleshooting tips for optimizing experimental outcomes.